Lung Cancer
From the Journals
Phase 1 study: Human IL-10 plus checkpoint blockade looks promising in RCC, NSCLC
Pegylated human IL-10 + anti–PD-1 therapy is well tolerated and shows promise for the treatment of both RCC and NSCLC.
Reviews
Clinical presentation, diagnosis, and management of typical and atypical bronchopulmonary carcinoid
From the Journals
Government insurance linked with lower likelihood of radiation therapy for limited-stage small cell lung cancer
Medicare/Medicaid had no impact on chemotherapy administration but was independently associated with lower likelihood of radiation therapy...
From the Journals
Sequential chemotherapy and radiotherapy may be best in locally advanced NSCLC with negative margins
For patients with R0 pN2 NSCLC, median overall survival was 58.8 months for sequential chemotherapy followed by radiation, versus 40.4 months for...
New Therapies
Expanding treatment options for diverse neuroendocrine tumors
Community Translations
Brigatinib approval yields additional treatment options for crizotinib-resistant, ALK-positive NSCLC patients
Conference Coverage
Ultrathin bronchoscopy plus radial EBUS unreliable at making diagnoses
Researchers made diagnoses for fewer than half of patients who had their nodules evaluated using ultrathin bronchoscopy plus radial EBUS.
Conference Coverage
First-in-class glutaminase inhibitor combats anti-PD-1/PD-L1 resistance
NATIONAL HARBOR, MD. – Responses in melanoma patients who were progressing on nivolumab at study entry and who were refractory to multiple prior...
Conference Coverage
ENCORE 601 study: Entinostat shows promise in NSCLC
Entinostat given in combination with pembrolizumab demonstrated antitumor activity and acceptable safety in patients with NSCLC in the phase 1b/2...
News
Breakthrough cancer gene assay approved, CMS proposes coverage
FDA approves first breakthrough-designated, next-generation sequencing assay that can detect genetic mutations in 324 genes and two genomic...